Oral composition

Abstract

To provide an oral composition containing dl-α-tocopheryl 2-L-ascorbyl phosphate diester alkali metal salt and cetylpyridinium chloride, with reduced photodegradation of the dl-α-tocopheryl 2-L-ascorbyl phosphate diester alkali metal salt.SOLUTION: An oral composition includes dl-α-tocopheryl 2-L-ascorbyl phosphate diester alkali metal salt, cetylpyridinium chloride, and at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof.SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to an oral composition containing dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, cetylpyridinium chloride, and at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof, a method for producing the composition, and a method for suppressing the promotion of photodegradation of dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt by cetylpyridinium chloride, etc.

Background Art

[0002] Dl-α-tocopherol 2-L-ascorbic acid phosphate diester (which may be referred to as "EPC" in this specification) is a compound in which ascorbic acid (vitamin C) and tocopherol (vitamin E) are ester-bonded via phosphoric acid, and is an amphiphilic substance having a hydrophilic group and a lipophilic group. The alkali metal salt of EPC has an antioxidant action and a moisturizing action and is used in cosmetics such as hair tonics (Patent Document 1).

[0003] In recent years, it has been found that the alkali metal salt of EPC can exhibit an anti-periodontal disease action, etc., and the incorporation of the alkali metal salt of EPC into oral compositions has been studied (Patent Document 2).

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0005] Cetylpyridinium chloride is a compound having a bactericidal action and is a frequently used component in the field of oral compositions for the purpose of sterilizing the causative bacteria of bad breath and periodontal disease. The present inventors expected that both the anti-periodontal disease action of the EPC alkali metal salt and the bactericidal action of cetylpyridinium chloride would be exhibited, and thus examined the combined use of the EPC alkali metal salt and cetylpyridinium chloride in an oral composition.

[0006] However, unexpectedly, as described below, in the oral composition containing the EPC alkali metal salt and cetylpyridinium chloride, the photodegradation of the EPC alkali metal salt was significantly accelerated (Test Example 1). Therefore, the present inventors mainly aimed to provide an oral composition containing the EPC alkali metal salt and cetylpyridinium chloride and suppressing the photodegradation of the EPC alkali metal salt.

Means for Solving the Problems

[0007] The present inventors found that the above problems could be solved by an oral composition containing at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof, in addition to the EPC alkali metal salt and cetylpyridinium chloride. And through further improvements, the present disclosure has been completed.

[0008] The present disclosure includes, for example, the subject matters described in the following items. Item 1. (A) dl-α-Tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, (B) Cetylpyridinium chloride, and (C) At least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof An oral composition for human use containing the same. Item 2. The oral composition according to claim 1, wherein the mass ratio (A / B) of the content of the component (A) to the content of the component (B) is 30 or less. Claim 3. The oral composition according to claim 1 or 2, wherein the value obtained by dividing the value of A / B by the content (% by mass) of the component (C) ((A / B) / C) is 30,000 or less. Claim 4. Furthermore, the oral composition according to any one of claims 1 to 3, which contains (D) polyoxyethylene hydrogenated castor oil. Claim 5. The oral composition according to any one of claims 1 to 4, wherein the content of the component (A) is 0.001 to 1% by mass. Claim 6. The oral composition according to any one of claims 1 to 5, wherein the component (A) is (a) dl-α-tocopherol 2-L-ascorbic acid phosphate diester potassium salt. Claim 7. In the oral composition for humans, (A) dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, (B) cetylpyridinium chloride, and (C) at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof is included, A method for suppressing the photo-degradation promotion of the component (A) by the component (B) in the oral composition.

Advantages of the Invention

[0009] According to the present disclosure, there is provided an oral composition containing an EPC alkali metal salt and cetylpyridinium chloride, and having suppressed photo-degradation of the EPC alkali metal salt.

Embodiments for Carrying Out the Invention

[0010] Hereinafter, each embodiment included in the present disclosure will be described in more detail. The present disclosure preferably includes, but is not limited to, oral compositions, methods for producing oral compositions, methods for suppressing the photocatalysis of EPC alkali metal salts by cetylpyridinium chloride, etc. The present disclosure includes all that is disclosed herein and can be recognized by those skilled in the art.

[0011] The oral composition included in the present disclosure contains (A) dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, (B) cetylpyridinium chloride, and (C) at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof. Hereinafter, the oral composition included in the present disclosure may be referred to as "the oral composition of the present disclosure".

[0012] 1. Oral composition of the present disclosure 1-1. Component (A) As described above, the oral composition of the present disclosure contains component (A): dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt. In the present disclosure, dl-α-tocopherol 2-L-ascorbic acid phosphate diester may be denoted as EPC. EPC is a compound in which ascorbic acid (vitamin C) and tocopherol (vitamin E) are ester-bonded via phosphoric acid, and is also referred to as (ascorbyl / tocopheryl) phosphate. The chemical formula of EPC is shown below.

Chemical formula

[0013] Examples of the EPC alkali metal salt include EPC potassium salt, EPC sodium salt, EPC lithium salt, etc. Among them, EPC potassium salt is preferred. Also, the EPC alkali metal salt may be a mono-salt or a di-salt. The EPC alkali metal salt can be used alone or in combination of two or more.

[0014] In the oral composition of the present disclosure, the content of component (A) is not particularly limited as long as the effects of the present disclosure are achieved, and can be, for example, 0.001 to 1% by mass. From the viewpoint of efficiently exerting the anti-periodontal disease effect and the like, the range is preferably 0.002 to 0.5% by mass, more preferably 0.005 to 0.3% by mass, and particularly preferably 0.01 to 0.2% by mass. The upper or lower limit of the range may be, for example, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, or 0.95% by mass.

[0015] 1-2. Component (B) As described above, the oral composition of the present disclosure contains component (B): cetylpyridinium chloride. Cetylpyridinium chloride is a compound having a bactericidal action. The chemical formula of cetylpyridinium chloride is shown below.

Chemical formula

[0016] In the oral composition of the present disclosure, the content of the component (B) is not particularly limited as long as the effects of the present disclosure are achieved, and can be, for example, 0.001 to 1% by mass. From the viewpoint of effectively exerting the bactericidal action, the range is preferably 0.002 to 0.8% by mass, more preferably 0.005 to 0.5% by mass, still more preferably 0.01 to 0.3% by mass, and particularly preferably 0.01 to 0.05% by mass. The upper or lower limit of the range may be, for example, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, or 0.95% by mass.

[0017] In the oral composition of the present disclosure, the mass ratio (A / B) of the content of component (A) to the content of component (B) is not particularly limited as long as the effects of the present disclosure are achieved, and can be, for example, 40 or less. From the viewpoint of efficiently suppressing the photodegradation of component (A), the range is preferably 30 or less, more preferably 25 or less, and particularly preferably 20 or less. The lower limit of the range is not particularly limited and may be any value greater than 0. The range may be, for example, 0.0001 to 40. The upper or lower limit of the range may be, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40.

[0018] 1-3. Component (C) As described above, the oral composition of the present disclosure contains at least one antioxidant selected from the group consisting of component (C): ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof. The chemical formula of ascorbic acid is shown below. [Chemical formula] The chemical formula of erythorbic acid is shown below. [Chemical formula] As understood from the above chemical formulas, ascorbic acid and erythorbic acid are in a relationship of stereoisomers with each other.

[0019] In the present disclosure, the derivatives of ascorbic acid and / or erythorbic acid are not particularly limited in their structure as long as the derivatives can exhibit an antioxidant effect. For example, ascorbic acid and / or erythorbic acid may have a structure in which at least one selected from the group consisting of phosphoric acid; glucose; glycerin; higher alcohols such as octanol; and fatty acids such as stearic acid, palmitic acid, and isopalmitic acid is bonded. Further, at least one of any hydroxyl groups of ascorbic acid and / or erythorbic acid may be substituted with an alkoxy group such as a methoxy group or an ethoxy group.

[0020] Examples of ascorbic acid derivatives include ascorbic acid phosphate esters, ascorbic acid glucosides, alkylglyceryl ascorbic acids, ascorbic acid fatty acid esters, alkyl ascorbic acids, etc. The number of carbon atoms in the alkyl group of alkylglyceryl ascorbic acid is not particularly limited, but may be, for example, 4 to 18, preferably 6 to 16, more preferably 6 to 10, and particularly preferably 8. The number of carbon atoms in the fatty acid group of ascorbic acid fatty acid ester is not particularly limited, but may be, for example, 6 to 22, preferably 10 to 20, more preferably 12 to 18, and particularly preferably 16 to 18. The number of carbon atoms in the alkyl group of alkyl ascorbic acid is not particularly limited, but may be, for example, 1 to 5, preferably 1 to 3, more preferably 1 to 2, and particularly preferably 2. Also, the alkyl group and the fatty acid group may be linear or branched. More specifically, examples of ascorbic acid derivatives include glyceryl octyl ascorbic acid, ascorbyl palmitate, ascorbyl palmitate phosphate, ethyl ascorbic acid, etc. Note that the ascorbic acid derivatives in component (C) of the present disclosure do not include component (A).

[0021] As ascorbic acid derivatives, specifically, ascorbic acid phosphate ester, ascorbic acid glucoside, alkyl glyceryl ascorbic acid, ascorbic acid fatty acid ester, alkyl ascorbic acid, etc. may be mentioned. The carbon number of the alkyl group of alkyl glyceryl ascorbic acid is not particularly limited, but for example, it may be 4 to 18 carbon atoms, preferably 6 to 16 carbon atoms, more preferably 6 to 10 carbon atoms, and particularly preferably 8 carbon atoms. The carbon number of the fatty acid group of ascorbic acid fatty acid ester is not particularly limited, but for example, it may be 6 to 22 carbon atoms, preferably 10 to 20 carbon atoms, more preferably 12 to 18 carbon atoms, and particularly preferably 16 to 18 carbon atoms. The carbon number of the alkyl group of alkyl ascorbic acid is not particularly limited, but for example, it may be 1 to 5 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms, and particularly preferably 2 carbon atoms. Further, the alkyl group and the fatty acid group may be linear or branched.

[0022] In the present disclosure, the phenolic antioxidant refers to a compound having a phenol skeleton and having an antioxidant action. Specific examples of the phenolic antioxidant include, for example, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), tert-butylhydroquinone (TBHQ), 4-hydroxymethyl-2,6-di-tert-butylphenol (HMBP), 2,4,5-trihydroxy-butyrophenone (THBP), tocopherol, tocotrienol, gallic acid, propyl gallate, and triamyl gallate. Here, the term "tocopherol" preferably includes any of α-tocopherol, β-tocopherol, γ-tocopherol, and δ-tocopherol, and also preferably includes any of their D-form, L-form, and racemic (DL)-form. Similarly, the term "tocotrienol" here preferably includes any of α-tocotrienol, β-tocotrienol, γ-tocotrienol, and δ-tocotrienol, and also preferably includes any of their D-form, L-form, and racemic (DL)-form.

[0023] From the viewpoints of safety to the human body and efficiently suppressing the photodegradation of component (A), etc., in the present disclosure, the phenolic antioxidant is preferably at least one selected from the group consisting of butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), tocopherol, and tocotrienol, and particularly preferably at least one selected from the group consisting of BHA, BHT, and α-tocopherol.

[0024] The chemical formula of BHA is shown below. Generally, BHA is commercially available in the form of a mixture of two structural isomers, 2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole shown below.

Chemical formula

Chemical formula

Chemical formula

[0025] In the present disclosure, component (C) may be a chemically acceptable salt of at least one compound selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, and phenolic antioxidants. Such salts include, for example, salts with inorganic bases such as aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, potassium salts, sodium salts, and zinc salts, etc. In particular, it is preferably a magnesium salt, a potassium salt, or a sodium salt. Also, for example, salts with organic bases include salts of primary, secondary, or tertiary amines. Specific amines include, for example, arginine, betaine, caffeine, choline-N-N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine-N-ethylmorpholine-N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxocobalamin, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, cinnamic acid, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, and tromethamine, etc.

[0026] In the present disclosure, it is particularly preferred that component (C) is at least one selected from the group consisting of ascorbic acid, sodium ascorbate, sodium erythorbate, BHA, BHT, and α-tocopherol.

[0027] In the oral composition of the present disclosure, the value obtained by dividing the value of A / B by the content (% by mass) of component (C) ((A / B) / C) is not particularly limited as long as the effects of the present disclosure are achieved, and can be, for example, 40,000 or less. From the viewpoint of efficiently suppressing the photodegradation of component (A), the range is preferably 30,000 or less, more preferably 25,000 or less, and particularly preferably 20,000 or less. The lower limit of the range is not particularly limited and may be any value greater than 0. The range may be, for example, 0.0001 to 40,000, preferably 0.1 to 30,000, more preferably 1 to 25,000, and particularly preferably 10 to 20,000. The upper limit or lower limit of the range may be, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 15000, 20000, 25000, 30000, 35000, or 40000.

[0028] Also, in the oral composition of the present disclosure, the mass ratio (A / C) of the content of component (A) to the content of component (C) is not particularly limited, and can be, for example, from 0.01 to 1000. From the viewpoint of efficiently suppressing the photodegradation of component (A), the range is preferably from 0.01 to 800, more preferably from 0.05 to 500, still more preferably from 0.1 to 300, and particularly preferably from 0.5 to 200. The upper or lower limit of the range may be, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000.

[0029] In the oral composition of the present disclosure, the content of component (C) is not particularly limited as long as the effects of the present disclosure can be achieved, and for example, it can be 0.0001 to 1% by mass. From the viewpoint of efficiently suppressing the photodegradation of component (A), this range is preferably 0.0002 to 0.8% by mass, more preferably 0.0005 to 0.7% by mass, still more preferably 0.001 to 0.6% by mass, and particularly preferably 0.001 to 0.5% by mass. The upper or lower limit of this range may be, for example, 0.0001, 0.0005, 0.001, 0.002, 0.0025, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1% by mass.

[0030] 1-4. Component (D) Although not particularly limited, the oral composition of the present disclosure preferably contains, in addition to the above-described components (A) to (C), further component (D): polyoxyethylene hydrogenated castor oil. When the oral composition of the present disclosure contains component (D), an excellent effect of suppressing the photodegradation of the EPC alkali metal salt can be achieved.

[0031] The average number of moles of ethylene oxide added to the polyoxyethylene hydrogenated castor oil that can be contained in the oral composition of the present disclosure is not particularly limited, and may be, for example, 5 to 150, may be 10 to 120, preferably 20 to 100, and more preferably 40 to 80. The upper or lower limit of the above range may be 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 95, 100, 110, 120, 130, 140, or 150. The polyoxyethylene hydrogenated castor oil can be used alone or in combination of two or more. In the present disclosure, the polyoxyethylene hydrogenated castor oil with an average number of moles of ethylene oxide added of X may be referred to as "POE(X) hydrogenated castor oil". For example, "POE(60) hydrogenated castor oil" refers to the polyoxyethylene hydrogenated castor oil with an average number of moles of ethylene oxide added of 60.

[0032] When the oral composition of the present disclosure contains component (D), its content is not particularly limited, and can be, for example, 0.001 to 10% by mass. The above range is preferably 0.01 to 8% by mass, more preferably 0.05 to 5% by mass, and even more preferably 0.1 to 2% by mass. The upper or lower limit of the above range may be, for example, 0.001, 0.005, 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10% by mass.

[0033] When the oral composition of the present disclosure contains component (D), the mass ratio (A / D) of the content of component (A) to the content of component (D) is not particularly limited, and can be, for example, 0.001 to 1. The said range is preferably 0.005 to 0.5, more preferably 0.01 to 0.3, and even more preferably 0.05 to 0.15. The upper limit or lower limit of the said range can be, for example, 0.001, 0.005, 0001, 0.02, 0.025, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.125, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1.

[0034] When the oral composition of the present disclosure contains component (D), the mass ratio (B / D) of the content of component (B) to the content of component (D) is not particularly limited, and can be, for example, 0.0001 to 1. The said range is preferably 0.0005 to 0.5, more preferably 0.001 to 0.3, even more preferably 0.005 to 0.1, and particularly preferably 0.01 to 0.06. The upper limit or lower limit of the said range can be, for example, 0.0001, 0.0005, 0.001, 0.002, 0.0025, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06, 0.065, 0.07, 0.075, 0.08, 0.085, 0.09, 0.095, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1.

[0035] 1-5. Other optional components In addition to the above-described components (A) to (C) and optionally component (D), the oral composition of the present disclosure may further contain optional components that can be incorporated into the oral composition, such as surfactants other than component (D), flavoring agents, sweetening agents, wetting agents, binders, preservatives, coloring agents, pH adjusters, abrasives, and medicinal components other than EPC alkali metal salts and cetylpyridinium chloride, either singly or in combination of two or more.

[0036] For example, as the surfactant other than component (D), at least one selected from the group consisting of nonionic surfactants, anionic surfactants, and amphoteric surfactants can be blended.

[0037] Specifically, for example, as nonionic surfactants, polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, polyoxyalkylene sorbit fatty acid esters, polyoxyalkylene glycerin fatty acid esters, polyoxyalkylene fatty acid amides, polyoxyalkylene glycol fatty acid esters, polyoxyalkylene castor oil derivatives, polyoxyalkylene hydrogenated castor oil other than component (D), polyoxyalkylene hydrogenated castor oil derivatives, polyglycerol fatty acid esters, monoglycerol fatty acid esters, sorbitan fatty acid esters, sorbit fatty acid esters, alkylene glycol fatty acid esters, alkyl polyglycosides, sugar fatty acid esters (such as sucrose fatty acid esters, maltose fatty acid esters, lactose fatty acid esters, etc.), fatty acid alkanolamides, diethyl sebacate, and the like can be mentioned. When the nonionic surfactant has a polyoxyalkylene moiety, the polyoxyalkylene moiety is preferably a polyoxyethylene moiety.

[0038] Examples of anionic surfactants include sulfate esters such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; acyl amino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methyl alaninate; and acyl methyl taurine salts such as sodium cocoyl methyl taurine.

[0039] Examples of amphoteric surfactants include betaine-type surfactants such as lauryldimethylaminoacetic acid betaine and coconut fatty acid amidopropyldimethylaminoacetic acid betaine; and imidazoline-type surfactants such as sodium N-cocoyl-N-carboxymethyl-N-hydroxyethyl ethylenediamine. The surfactants can be formulated alone or in combination of two or more.

[0040] As flavoring agents, for example, menthol, carvone, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronellol, α-terpineol, methyl acetate, citronellyl acetate, methyl eugenol, cineole, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, galbanum oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, pimento oil, d-camphor, d-borneol, star anise oil, cinnamon oil, cinnamaldehyde, peppermint oil, vanillin and other fragrances can be used. The flavoring agents can be formulated alone or in combination of two or more.

[0041] Examples of sweeteners include sodium saccharin, acesulfame potassium, stevia, stevioside, neohesperidin dihydrochalcone, perillartine, thaumatin, aspartyl phenylalanine methyl ester, p-methoxycinnamic aldehyde, etc. The sweeteners can be formulated alone or in combination of two or more.

[0042] As wetting agents, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, etc. can be formulated alone or in combination of two or more.

[0043] As binders, cellulose derivatives such as sodium carboxymethyl cellulose, carboxymethyl ethyl cellulose salt, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, crystalline cellulose, crystalline cellulose - sodium carmellose, etc., microbial - produced polymers such as xanthan gum, natural polymers or natural gums such as tragacanth gum, karaya gum, gum arabic, carrageenan, dextrin, agar, pectin, pullulan, gellan gum, locust bean gum, sodium alginate, etc., synthetic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, polyvinyl methyl ether, sodium polyacrylate, etc., inorganic binders such as thickening silica, beegum, etc., and cationic binders such as O - [2 - hydroxy - 3 - (trimethylammonio)propyl] hydroxyethyl cellulose hydrochloride can be mentioned. The binders can be used alone or in combination of two or more.

[0044] As preservatives, parabens such as methylparaben, ethylparaben, propylparaben, butylparaben, etc., sodium benzoate, phenoxyethanol, alkyl diaminethyl glycine hydrochloride, etc. can be formulated. The preservatives can be used alone or in combination of two or more.

[0045] As colorants, legal dyes such as Blue No. 1, Yellow No. 4, Red No. 202, Green No. 3, etc., mineral - based dyes such as ultramarine, fortified ultramarine, dark ultramarine, etc., titanium oxide, etc. may be formulated. The colorants can be used alone or in combination of two or more.

[0046] As a pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or their chemically possible salts, sodium hydroxide, etc. may be blended. The pH adjuster can be blended singly or in combination of two or more so that the pH of the oral composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjuster may be, for example, 0.01 to 2 mass%.

[0047] Examples of the abrasive include calcium carbonate, magnesium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium phosphate, silica, zeolite, sodium metaphosphate, aluminum hydroxide, magnesium hydroxide, calcium pyrophosphate, bengala, calcium sulfate, anhydrous silicic acid, etc. The abrasive can be used singly or in combination of two or more.

[0048] In the oral composition of the present disclosure, as medicinal ingredients other than the EPC alkali metal salt and cetylpyridinium chloride, further, amphoteric bactericides such as dodecyldiaminoethylglycine, nonionic bactericides such as isopropylmethylphenol and triclosan, anionic bactericides such as sodium lauroyl sarcosinate, cationic bactericides such as chlorhexidine hydrochloride, benzalkonium chloride, and benzethonium chloride, enzymes such as dextranase, amylase, protease, mutanase, lysozyme, and lysing enzyme (lytech enzyme), alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate, fluorides such as sodium fluoride and stannous fluoride, tranexamic acid, epsilon aminocaproic acid, aluminum chlorohydrol allantoin, allantoin, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizic acid, metal salts of glycyrrhizic acid, hinokitiol, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, caropeptide, pyridoxine hydrochloride, carbazochrom, potassium nitrate, paratinit, etc. can be blended singly or in combination of two or more.

[0049] In addition, as a base, it is also possible to add water, alcohols, silicones, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastic base, etc. These can be blended singly or in combination of two or more.

[0050] 1-6. Others As described above, in recent years, it has been found that EPC alkali metal salts can exhibit an anti-periodontal disease effect and the like. In addition, cetylpyridinium chloride is a compound having a bactericidal action and is a frequently used component in the field of oral compositions for the purpose of sterilizing the causative bacteria of halitosis and periodontal disease. The inventors of the present invention expected that both the anti-periodontal disease action of the EPC alkali metal salt and the bactericidal action of cetylpyridinium chloride would be exhibited, and when considering the combined use of the EPC alkali metal salt and cetylpyridinium chloride in an oral composition, a new problem was found that the photodegradation of the EPC alkali metal salt was significantly accelerated in the oral composition containing the EPC alkali metal salt and cetylpyridinium chloride.

[0051] The inventors of the present invention further conducted extensive studies and found that the photodegradation of the EPC alkali metal salt can be suppressed by adding at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof to the oral composition containing the EPC alkali metal salt and cetylpyridinium chloride. That is, in the oral composition of the present disclosure containing components (A) to (C), the photodegradation of the EPC alkali metal salt can be suppressed, so that both the anti-periodontal disease action of the EPC alkali metal salt and the bactericidal action of cetylpyridinium chloride can be effectively exhibited. Therefore, the oral composition of the present disclosure can be suitably used for the sterilization of oral bacteria including the causative bacteria of halitosis and periodontal disease and for anti-periodontal disease applications.

[0052] The application targets of the oral composition of the present disclosure include mammals including humans (such as dogs, cats, mice, rats, sheep, horses, cows, monkeys, etc.), and among them, humans are preferred. Examples of humans who are the application targets of the oral composition of the present disclosure include, for example, periodontal disease patients or humans suspected of having periodontal disease, humans who want to prevent the onset of periodontal disease, humans who want to suppress the progression of periodontal disease, humans at high risk of periodontal disease (the elderly, smokers, humans with high blood sugar levels, etc.), humans who want to keep their oral cavity clean, and the like.

[0053] The dosage form of the oral composition of the present disclosure is not particularly limited, and can be a solid composition, a semi-solid composition, a liquid composition, etc. More specifically, for example, it may be in dosage forms such as ointments, pastes, pastas, gels, liquids, sprays, mouthwashes, liquid dentifrices, kneaded dentifrices, gums, tablets, drops, etc. Among them, ointments, pastes, gels, liquids, mouthwashes, liquid dentifrices, and kneaded dentifrices are preferred.

[0054] The preparation method of the oral composition of the present disclosure is not particularly limited as long as the effects of the present disclosure are achieved. For example, it can be prepared according to methods known in the art. More specifically, for example, it can be prepared by appropriately mixing components (A) to (C) and optionally component (D), as well as other components.

[0055] 2. Method of the present disclosure The present disclosure also includes a method for suppressing the photo-degradation promotion of component (A) by component (B) in the oral composition by including in the oral composition (A) dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, (B) cetylpyridinium chloride, and (C) at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof. This method may be referred to as "the method of the present disclosure" in the present disclosure. The matters described in the section of "1. The oral composition of the present disclosure" are incorporated by reference into the method of the present disclosure.

[0056] In an oral composition, whether the promotion of photodegradation of component (A) by component (B) is suppressed by containing component (C) can be evaluated by a conventionally known method or a method that can be easily conceived by those skilled in the art from a conventionally known method. For example, an oral composition containing component (A), component (B), and component (C) and an oral composition containing component (A) and component (B) but not containing component (C) are prepared. After irradiating both with light for a certain period of time, it can be evaluated by analyzing the residual ratio of component (A) by HPLC. When the residual ratio of component (A) in the former is higher than that in the latter, it can be determined that the promotion of photodegradation of component (A) by component (B) is suppressed by containing component (C).

[0057] 3. Manufacturing method of the present disclosure The present disclosure also includes a method for producing an oral composition, which includes a step of mixing (A) dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, (B) cetylpyridinium chloride, and (C) at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof. This production method may be referred to as "the production method of the present disclosure."

[0058] The matters described in the sections of "1. The oral composition of the present disclosure" and "2. The method of the present disclosure" are incorporated by reference into the production method of the present disclosure.

[0059] In addition, in this specification, "comprising" includes, in addition to "containing," "essentially consisting of" and "consisting of" (The term “comprising” includes “essentially consisting of” and ”consisting of.“). The present disclosure also includes any combination of the constituent elements described in this specification.

[0060] Moreover, the various characteristics (numerical values, properties, structures, functions, etc.) described for each embodiment of the present disclosure above may be combined in any way when specifying the subject matter encompassed by the present disclosure. That is, the present disclosure encompasses all subject matters consisting of any combination of the combinable characteristics described in this specification.

Example

[0061] Hereinafter, the embodiments of the present disclosure will be described more specifically with examples, but the embodiments of the present disclosure are not limited to the following examples. Unless otherwise specified hereinafter, % represents mass %. In this example, the EPC potassium salt may be simply referred to as "EPC", and cetylpyridinium chloride may be referred to as "CPC".

[0062] Test Example 1. Oral composition containing EPC alkali metal salt and cetylpyridinium chloride An oral composition (mouthwash) was prepared according to the composition described in Table 1. The oral composition was prepared by dissolving other components in purified water. In this example, "POE(60) hydrogenated castor oil" refers to polyoxyethylene hydrogenated castor oil with an average addition mole number of ethylene oxide of 60.

Table 1

[0063] Each prepared oral composition was filled into a colorless and transparent resin container and left standing in a light stability tester (product name: LST-2010, Tokyo Rikakikai Co., Ltd.) for 10 days. More specifically, the test conditions in the light stability tester were a temperature of 25°C, a humidity of 0%, and an illuminance of 10,000 lux (lx). Also, as a control, each oral composition was filled into a colorless and transparent resin container and left standing in the dark at -5°C for 10 days.

[0064] After 10 days, the remaining rate of EPC (%) in each oral composition was analyzed using high-performance liquid chromatography (HPLC). The remaining rate of EPC was calculated with the amount of EPC contained in the control left standing in the dark at -5°C for 10 days as 100%. The results are shown below Table 1. In this example, a remaining rate of EPC of 90% or more was rated as ◎, a remaining rate of EPC of 81% or more and less than 90% was rated as ○, and a remaining rate of EPC of less than 81% was rated as ×.

[0065] As shown in Table 1, in Reference Example 1 which did not contain cetylpyridinium chloride, the remaining rate of EPC was high. On the other hand, in Comparative Examples 1 and 2 which contained cetylpyridinium chloride, the remaining rate of EPC was significantly low. Particularly in Comparative Example 2, the remaining rate of EPC was only 7.4%.

[0066] From the results of this test example, unexpectedly, it was found that in an oral composition containing an alkali metal salt of EPC and cetylpyridinium chloride, the photodegradation of the alkali metal salt of EPC was significantly accelerated. In other words, it was suggested that cetylpyridinium chloride might promote the photodegradation of the alkali metal salt of EPC.

[0067] Test Example 2. Examination of technology for suppressing photodegradation of EPC alkali metal salt Based on the results of Test Example 1, the present inventors examined a technique for suppressing the photodegradation of the alkali metal salt of EPC in an oral composition containing the alkali metal salt of EPC and cetylpyridinium chloride.

[0068] Specifically, according to the compositions described in Tables 2 to 6, oral compositions (mouthwashes) were prepared. The oral compositions were prepared by dissolving the other components in purified water.

Table 2

Table 3

Table 4

Table 5

Table 6

[0069] Each prepared oral composition was filled into a colorless and transparent resin container and allowed to stand in a photo-stability tester for 10 days in the same manner as in Test Example 1. Also, as a control, each oral composition was filled into a colorless and transparent resin container and allowed to stand in the dark at -5°C for 10 days.

[0070] After each period elapsed, the residual rate (%) of EPC in each oral composition was analyzed by the method described in Test Example 1. The results are shown below Tables 2 to 6. The results of Comparative Example 1 and Comparative Example 2 are the results described again in Test Example 1.

[0071] As shown in Tables 2 to 6, the oral compositions of the examples containing component (C) showed a higher residual rate of EPC than each of the comparative examples not containing component (C).

[0072] Discussion From the results of this example, it was found that in the oral composition containing an EPC alkali metal salt and cetylpyridinium chloride, the photodegradation of the EPC alkali metal salt was significantly accelerated (Reference Example 1 and Comparative Examples 1 and 2). However, even in the oral composition containing an EPC alkali metal salt and cetylpyridinium chloride, when further containing at least one antioxidant selected from the group consisting of component (C): ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof, it was found that the photodegradation of the EPC alkali metal salt was suppressed (Examples 1 to 17).

[0073] In other words, from the results of this example, it was suggested that the promotion of photodegradation of the EPC alkali metal salt by cetylpyridinium chloride may be suppressed by the said component (C).

[0074] Also, as shown in the above table, Comparative Examples 1 and 2 contain Component (A) and Component (B) and do not contain Component (C) and Component (D), while Comparative Examples 4 and 5 contain Component (A), Component (B), and Component (D) and do not contain Component (C). From the comparison between Comparative Example 1 and Comparative Example 4 and the comparison between Comparative Example 2 and Comparative Example 5, it was suggested that Component (D): polyoxyethylene hydrogenated castor oil has a certain EPC alkali metal salt decomposition inhibitory effect. However, in Examples 13 to 17 which further contain Component (C) in addition to Component (D), the EPC residual rate was even higher than that of Comparative Examples 4 and 5 which do not contain Component (C).

[0075] From the above results, it was suggested that even in an oral composition in which the photodegradation promotion of the EPC alkali metal salt by cetylpyridinium chloride has already been suppressed to a certain extent by containing polyoxyethylene hydrogenated castor oil, further containing Component (C) may exhibit an even more excellent photodegradation inhibitory effect on the EPC alkali metal salt. That is, it was suggested that by containing Component (C) and polyoxyethylene hydrogenated castor oil in an oral composition containing an EPC alkali metal salt and cetylpyridinium chloride, a particularly excellent photodegradation inhibitory effect on the EPC alkali metal salt may be exhibited.

Claims

1. An oral composition for humans, containing: (A) an alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid phosphate diester; (B) cetylpyridinium chloride; and (C) at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof.

2. The oral composition according to Claim 1, wherein the mass ratio (A / B) of the content of the component (A) to the content of the component (B) is 30 or less.

3. The oral composition according to Claim 1 or 2, wherein the value obtained by dividing the value of A / B by the content (% by mass) of the component (C) ((A / B) / C) is 30,000 or less.

4. The oral composition according to Claim 1 or 2, further containing (D) polyoxyethylene hydrogenated castor oil.

5. The oral composition according to Claim 1 or 2, wherein the content of the component (A) is 0.001 to 1% by mass.

6. The oral composition according to Claim 1 or 2, wherein the component (A) is (a) potassium salt of dl-α-tocopherol 2-L-ascorbic acid phosphate diester.

7. A method for suppressing the photo-degradation acceleration of the component (A) by the component (B) in the oral composition, which includes adding (A) an alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid phosphate diester, (B) cetylpyridinium chloride, and (C) at least one antioxidant selected from the group consisting of ascorbic acid, ascorbic acid derivatives, erythorbic acid, erythorbic acid derivatives, phenolic antioxidants, and salts thereof to the oral composition for humans. ​

Images